Cipla is investing over R 1.3 billion ($91 million) to build a biotech manufacturing facility in South Africa for producing biosimilars that will be for both state and private sectors with potential to export to the United States, European Union, and Asia. The facility will be located in Durban, South Africa at the Department of Trade and Industries Special Economic Zone of Dube Tradeport.

Construction is slated to start in early 2017 with full operations expected to begin in the third quarter of 2018. At full capacity, the facility would create up to 300 jobs, primarily in the engineering and biological science fields.

This investment follows the launch of a new distribution center in 2015 by Cipla and a recent upgrade to an existing manufacturing facility in KwaZulu-Natal, the garden province of South Africa.

Source: Cipla